Background: The Spanish Registry PUBERE was created (2007) with 53 hospitals.
Objective and hypotheses: i) To determine the chronological age (CA) and bone (BA) at GnRH analogue withdrawal; ii) to analyze the age at menarche and time elapsed after stopping treatment; and iii) to know adult height data.
Method: Patients with central precocious puberty (CPP) born after 1992, diagnosed before 8 years in girls, with BA/CA >1 year and LH peak after LHRH >7 IU/l, were included. At diagnosis we calculated the adult height (AH) prediction (Bayley and Pineau method) in cm and SDS according to the reference population. We also collected data of GnRH analogue withdrawal (BA and CA), age at menarche and AH data (cm and SDS).
Results: 386 patients (19.9% adopted and 87.4% idiopathic) were included. The CA at treatment onset was 7.26±1.31 years and the BA 9.10±1.51 years. The average CA at treatment discontinuation was 10.15±1.01 years (n=186), coinciding with a BA of 11.6±0.67 years. The age at menarche was 11.04±1.14 years (n=106), occurring 13.52±7.14 months after stopping treatment. The mean increase in height after treatment discontinuation was 13.1±4.3 cm. Mean AH (n=30) was 157.5±11.03 cm (SDS: −0.66±1.98). The mean PAH at diagnosis was 161.5±10.9 cm, so the mean difference between AH and PAH at diagnosis was −3.76±8.61 cm (95% CI: −6.98 to −0.55 cm; P=0.023).
Conclusion: i) The AH of PPC patients was significantly lower than their PAH, but within the margin of error of this method (95% CI: ±6 cm). ii) Treatment withdrawal was done before the age of pubertal onset average in our population. iii) Menarche occured about 13 months after stopping treatment.
20 - 22 Sep 2014
European Society for Paediatric Endocrinology